Bulletin Du Cancer最新文献

{"title":"Title Page","authors":"","doi":"10.1016/S0007-4551(25)00146-8","DOIUrl":"10.1016/S0007-4551(25)00146-8","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 3","pages":"Page i"},"PeriodicalIF":1.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143706041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copyright Page","authors":"","doi":"10.1016/S0007-4551(25)00148-1","DOIUrl":"10.1016/S0007-4551(25)00148-1","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 3","pages":"Page iv"},"PeriodicalIF":1.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143706043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommandations de la prise en charge des CBNPC oligométastatiques","authors":"Alice Mogenet ,&nbsp;Laurent Greillier ,&nbsp;Pascale Tomasini","doi":"10.1016/S0007-4551(25)00162-6","DOIUrl":"10.1016/S0007-4551(25)00162-6","url":null,"abstract":"<div><div>Le concept de maladie oligométastatique dans le cancer bronchique a été l'objet de nombreuses publications et spéculations. En effet, au-delà de sa définition qui fait encore débat, il s'agit d'un concept assez large en prenant en compte la maladie oligométastatique synchrone mais également les concepts d'oligoprogression et d'oligopersistance, d'autant plus fréquent avec l'amélioration de l'efficacité des traitements systémiques ces dernières années. Bien qu'aucun essai prospectif randomisé ne permette aujourd'hui de trancher la question, il semble pertinent de proposer aux patients un traitement local en cas d'oligoprogression <em>a fortiori</em>symptomatique et en cas d'addiction oncogénique. Les données les plus récentes ne plaident en revanche pas pour la réalisation d'un traitement de clôture pour les patients répondeurs à l'immunothérapie. Au total, il est important de retenir que le traitement systémique reste la pierre angulaire du traitement du cancer bronchique métastatique et que de nouvelles études robustes randomisées seront nécessaires pour trancher sur la place du traitement local.</div></div><div><div>The concept of oligometastatic disease in lung cancer has been the subject of much publication and speculation. Indeed, beyond its definition, which is still a matter of debate, it is a rather broad concept considering synchronous oligometastatic disease but also oligoprogression and oligopersistence concepts. These questions are increasingly common considering the improvement of systemic treatments in recent years. Although no prospective randomized trial has been conducted to date, it would seem appropriate to offer patients local ablative treatment of oligoprogression, especially if symptomatic or in cases of oncogenic addiction. On the other hand, the most recent data do not defend the closure treatment approach for patients who benefit from immunotherapy. All in all, it is important to remember that systemic therapy remains the cornerstone of treatment for metastatic lung cancer, and that further robust randomized studies will be needed to determine the place of local therapy.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 3","pages":"Pages 3S95-3S99"},"PeriodicalIF":1.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143706088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MG149 suppresses anaplastic thyroid cancer progression by inhibition of lysine acetyltransferase KAT5-mediated c-Myc acetylation","authors":"Pan Sheng ,&nbsp;Zhen Chen ,&nbsp;Junjun Wen ,&nbsp;Chuanming Tong ,&nbsp;Ju Wang ,&nbsp;Zhengwen Du","doi":"10.1016/j.bulcan.2024.11.008","DOIUrl":"10.1016/j.bulcan.2024.11.008","url":null,"abstract":"<div><h3>Background</h3><div>Anaplastic thyroid cancer (ATC) is a highly lethal form of thyroid cancer. lysine acetyltransferase 5 (KAT5) has been found to promote ATC development via c-Myc stabilization by previous study. We thus designed experiments to confirm the anti-tumor effect of a KAT5 inhibitor (MG149) in ATC.</div></div><div><h3>Methods</h3><div>Western blotting assessed the level of KAT5, c-Myc, and epithelial-mesenchymal transition (EMT)-related proteins in ATC cells and xenograft tumor tissues. Cell counting kit-8, flow cytometry, wound healing, and transwell assays revealed the effect of MG149 on cell proliferation, apoptosis, migration, and invasion in ATC cell lines. Immunofluorescence detected the level of E-cadherin and N-cadherin in ATC cell lines. The effect of MG149 on KAT5-mediated c-Myc stabilization was detected using co-immunoprecipitation assay. Tumor volume and tumor weight in ATC xenograft models were evaluated. H&amp;E staining showed the effect of MG149 on lung metastasis in vivo. We further investigated whether MG149 can enhance the sensitivity of ATC to cisplatin (CDDP).</div></div><div><h3>Results</h3><div>MG149 inhibited cell proliferation and increased the apoptosis of cells. MG149 suppressed the migratory and invasive ability of ATC cells. The EMT in CAL-62 and 8505<!--> <!-->C cells was significantly inhibited by MG149. MG149 suppressed the KAT5-mediated c-Myc acetylation. MG149 inhibited tumor growth and lung metastasis in vivo. Additionally, MG149 potentiated the sensitivity to CDDP in ATC cells in vitro and in vivo.</div></div><div><h3>Conclusion</h3><div>MG149 suppresses ATC progression and metastasis by inhibiting the acetylation of c-Myc mediated by KAT5.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 122-134"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ours redaction EDB","authors":"","doi":"10.1016/S0007-4551(25)00003-7","DOIUrl":"10.1016/S0007-4551(25)00003-7","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Page i"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143168352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum à l’article « Onco'sport à l’épreuve des patients : expérience vécue des patients atteints d’un cancer pratiquant de l’activité physique adaptée dans le cadre du programme Onco'sport, une étude qualitative » [Bull Cancer 2024;111:587–596]","authors":"Loïc Pages ,&nbsp;Estelle Gouin-Barré ,&nbsp;Céline Bourgier","doi":"10.1016/j.bulcan.2024.12.009","DOIUrl":"10.1016/j.bulcan.2024.12.009","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 236-237"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions des patients vis-à-vis de la téléconsultation dans le suivi à long terme après un cancer pédiatrique","authors":"Romane Requier ,&nbsp;Charlotte Demoor-Goldschmidt ,&nbsp;Amandine Bertrand ,&nbsp;Agnes Dumas","doi":"10.1016/j.bulcan.2024.10.012","DOIUrl":"10.1016/j.bulcan.2024.10.012","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Depuis une dizaine d’années, des « consultations de suivi à long terme » à destination des adultes guéris d’un cancer pédiatrique ont été créées pour assurer la prévention, la détection précoce et le traitement des effets à long terme. Désormais, celles-ci se déroulent parfois sous la forme d’une téléconsultation, pratique ayant connu un véritable essor à la suite de la crise du COVID-19. L’objectif de cette étude était d’évaluer la satisfaction, l’utilité, et le ressenti patient de la téléconsultation réalisée par un oncologue ou un hématologue dans le cadre d’un suivi à long terme d’adultes guéris d’un cancer pédiatrique. Il s’agit d’une étude descriptive multicentrique sur un échantillon de patients adultes guéris d’un cancer pédiatrique bénéficiant d’une téléconsultation de suivi à long terme. Pour chaque patient, un questionnaire de satisfaction a été envoyé à l’issue de la téléconsultation. Des analyses descriptives ont été réalisées pour l’ensemble des variables et des analyses bivariées ont été conduites entre les variables d’intérêt (satisfaction, confiance, utilité) et cinq co-variables (sexe, type de diagnostic, perception de l’état de santé, niveau d’études, expérience antérieure de la téléconsultation) à l’aide du test exact de Fisher. Concernant l’appréciation globale de leur expérience de la téléconsultation de suivi à long terme, 73 % des patients étaient très satisfaits et 25 % assez satisfaits. Ils étaient notamment tous satisfaits du temps de la consultation (88 %), estimant qu’ils avaient pu aborder les sujets qu’ils souhaitaient (83 %). Ainsi, 71 % des patients souhaiteraient pouvoir recourir à la téléconsultation à l’avenir.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;For the past decade, “long-term follow-up consultations” have been established for adults cured of pediatric cancer to ensure the prevention, early detection, and treatment of long-term effects. These consultations are now sometimes conducted in the form of teleconsultations, a practice that has seen significant growth following the COVID-19 crisis. The objective of this study was to evaluate the satisfaction, usefulness, and patient experience of teleconsultations conducted by an oncologist or hematologist as part of the long-term follow-up of adults cured of pediatric cancer. This is a descriptive multicenter study of a sample of adult patients cured of pediatric cancer who benefited from a long-term follow-up teleconsultation. After each teleconsultation, a satisfaction questionnaire was sent to the patient. Descriptive analyses were conducted for all variables, and bivariate analyses were performed between the variables of interest (satisfaction, trust, usefulness) and five covariates (gender, type of diagnosis, health status perception, education level, prior teleconsultation experience) using Fisher's exact test. Regarding the overall appreciation of their long-term follow-up teleconsultation experience, 73% of patients were very satisfied and 25% fairly satisfied. No","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 189-198"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of immune characteristics of two lung adenocarcinoma subtypes based on immune- and pyroptosis-related genes to improve immunotherapy","authors":"Yifan Tie ,&nbsp;Jinzhi Xu","doi":"10.1016/j.bulcan.2024.11.009","DOIUrl":"10.1016/j.bulcan.2024.11.009","url":null,"abstract":"<div><h3>Background</h3><div>Lung adenocarcinoma (LUAD) is the most prevalent histological subtype of lung cancer. Pyroptosis is a programmatic cell death linked to inflammation.</div></div><div><h3>Methods</h3><div>The data information of 541 LUAD samples and 59 normal samples were obtained from TCGA database. The analysis of differentially expressed genes (DEGs) was carried out on LUAD patients. The intersection of integrated PRGs and IRGs with DEGs yielded IPRGs. We utilized univariate Cox regression to determine IPRGs linked to overall survival (OS). Based on their expression levels, unsupervised clustering of LUAD was conducted. Patients were divided into two clusters. Analyses of immunity and drugs were performed in two clusters.</div></div><div><h3>Results</h3><div>One hundred and thirty-two IPRGs were linked with OS. Cluster 1 had a longer OS. Two thousand two hundred and fifty-six DEGs were detected in various subtypes. The results of immune analysis showed that most of the immune cells in cluster 2, which had a worse prognosis, had a low degree of infiltration. High Th2 cell infiltration may be related to poor prognosis in LUAD patients. Higher tumor immune dysfunction and exclusion (TIDE) and immunophenotypic scores in Cluster 1 indicated that these patients may have a better response to immunotherapy. There were significant differences in human leukocyte antigen (HLA), immune checkpoints, immunophenoscore (IPS), and TIDE scores in the two subtypes. The mutation frequencies of the top 10 genes in cluster 2 were higher than those in cluster 1. Different subtypes also had distinct sensitivities to different drugs.</div></div><div><h3>Conclusion</h3><div>IPRGs can be utilized for LUAD subtyping. Different subtypes have varied immune landscapes and immunotherapy responses.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 135-148"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Évaluation de l’expérience des patients en oncologie et pathologies chroniques : analyse critique des outils disponibles (PROMs, PREMs, Satisfaction)","authors":"Loubna Diouri ,&nbsp;Coralie Barbe ,&nbsp;Stéphane Vignot","doi":"10.1016/j.bulcan.2024.11.010","DOIUrl":"10.1016/j.bulcan.2024.11.010","url":null,"abstract":"&lt;div&gt;&lt;div&gt;L’évaluation de la qualité des soins a émergé à la fin des années 1990, conduisant à l’intégration des usagers dans les systèmes de santé. Afin d’intégrer la perception des patients, des ressources existent tels que les PRO (&lt;em&gt;Patient Reported Outcomes&lt;/em&gt;), les PROMs (&lt;em&gt;Patient-Reported Outcome Measures&lt;/em&gt;), la satisfaction et les patients experts ou partenaires. Les PREMs (&lt;em&gt;Patient-Reported Experience Measures)&lt;/em&gt; ont récemment émergé, apportant un regard nouveau pour l’amélioration de la qualité et des parcours de soins mais ils sont encore méconnus. L’objectif de cette étude est de réaliser une analyse critique des publications disponibles sur les outils d’évaluation de l’expérience vécue par le patient, dans son parcours de soins, pour une pathologie chronique avec un focus en oncologie et d’identifier les thèmes communs. Une recherche documentaire a été réalisée de juin 2023 à mars 2024. Elle s’est articulée autour des concepts de qualité de vie, de satisfaction et d’expérience vécue par le patient. Soixante-dix-neuf articles en lien avec l’expérience patient ont été identifiés dont 44 en oncologie et 35 hors oncologie. Les mesures analysées comprennent des questions d’expérience mais aussi des questions de satisfaction et/ou de mesures de PROMs. Néanmoins, elles s’adressent à des domaines concordants qui sont importants pour le patient. Cette étude a permis de constater un développement construit des PROMs et de la satisfaction des patients. Les PREMs et le recueil d’expérience patient sont encore nouveaux. Leurs utilisations restent centrées sur des étapes ciblées de prise en charge et les outils manquent pour évaluer le parcours plus globalement.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Care quality assessment emerged in the late 1990s, leading to the integration of users into healthcare systems. To integrate patient perceptions, resources such as PROs (Patient Reported Outcomes), PROMs (Patient-Reported Outcome Measures), satisfaction and patient experts or partners have been developed. PREMs (Patient-Reported Experience Measures) have recently emerged, bringing a fresh perspective to improving quality and care pathways, but are still little-known. The aim of this study is to carry out a critical analysis of available publications on tools for evaluating the patient's experience of the care pathway for a chronic disease, with a focus on oncology, and to identify common themes. A literature search was carried out from June 2023 to March 2024. It focused on the concepts of quality of life, satisfaction and patient experience. Seventy-nine articles related to patient experience were identified, including 44 in oncology and 35 outside oncology. The measures analyzed include experience questions as well as satisfaction questions and/or PROMs measures. Nevertheless, they address concordant domains that are important to the patient. This study has shown a consistent development of PROMs and patient satisfaction. PROMs and patient experience ","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 178-188"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of metastatic lung cancer in France between 2013 and 2021: Observational study using the French claims database","authors":"Christos Chouaid ,&nbsp;Clarisse Marchal ,&nbsp;Marion Apert ,&nbsp;Lionel Bensimon ,&nbsp;Valérie Guimard ,&nbsp;Mélanie Née ,&nbsp;Manon Belhassen ,&nbsp;Gérard de Pouvourville ,&nbsp;Jean-Yves Blay","doi":"10.1016/j.bulcan.2024.12.007","DOIUrl":"10.1016/j.bulcan.2024.12.007","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Treatment landscape in metastatic lung cancer has progressed quickly over the last decade, mainly due to immunotherapies and targeted therapies. This study aimed to describe change in epidemiological data of patients with metastatic lung cancer.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A cohort of patients identified between 2013 and 2021 with lung cancer and a marker of metastases (ICD-10 code or reimbursement for Bevacizumab or Pemetrexed) was built from the French claims database. A trend analysis of the rate of newly-diagnosed metastatic patients and the proportion of deaths over the study period was performed using Joinpoint® software.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Between 2013 and 2021, 147,760 metastatic lung cancer patients were identified (men: 66.5%, median age: 66 years). A statistically significant decrease in the crude rate of newly-diagnosed metastatic patients was observed in men (−1.18% per year in average), whereas a statistically significant increase was described in women (+2.36% per year in average). A downward trend in the proportion of deaths was found for both gender (−4.37% and −5.07% per year on average, respectively).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Discussion&lt;/h3&gt;&lt;div&gt;This study provides unpublished epidemiological data on metastatic lung cancer in France and confirms sex-differentiated trends in the rate of newly-diagnosed metastatic patients, already observed for all stages combined. A statistically significant decrease in the proportion of deaths among metastatic lung cancer patients is observed in both genders. These results underline the importance of ongoing investments in prevention and screening initiatives to reverse the incidence trends observed in women. Moreover, it highlights the criticality of therapeutic innovation in sustaining the increase in survival.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;L’offre thérapeutique dans le cancer du poumon métastatique a progressé rapidement ces dix dernières années, principalement grace aux immunothérapies et thérapies ciblées. Cette étude visait à décrire l’évolution des données épidémiologiques des patients avec un cancer du poumon métastatique.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthode&lt;/h3&gt;&lt;div&gt;Une cohorte de patients avec un cancer du poumon et un marqueur de métastases (code CIM-10 ou remboursement de bévacizumab ou pémétrexed) entre 2013 et 2021 a été constituée avec les données de remboursements françaises. Un test de tendance du taux de patients nouvellement diagnostiqués métastatique et de la proportion de décès a été réalisé avec le logiciel Joinpoint®.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Parmi les patients, 147 760 atteints de cancer du poumon métastatique ont été identifiés (hommes : 66,5 %, âge médian : 66 ans). Une diminution statistiquement significative du taux de patients nouvellement diagnostiqués métastatique chez les hommes (−1,18 % par an en moyenne) et une augmentation statistiquement significative chez les femmes (+2,36 % par an en moy","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 166-177"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}